echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Novartis Iskalizumab for kidney transplantation: not as effective as tacrolimus!

    Novartis Iskalizumab for kidney transplantation: not as effective as tacrolimus!

    • Last Update: 2021-09-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Novartis recently announced that it decided to terminate the study after an interim analysis of data from the Phase 2 CIRRUS-1 study (NCT03663335) of the cd40-targeted monoclonal antibody CFZ533 (iscalimab) for the treatment of kidney transplant patients


    Analysis shows that compared with tacrolimus treatment, cfz533 treatment is less effective in preventing organ rejection in kidney transplant patients


    The cirrus1 study evaluated 418 transplant patients and studied 3 different doses of CFZ533, aiming to evaluate the anti-rejection ability of CFZ533 instead of calcineurin inhibitors (CNI), while having better renal function and better safety.


    Novartis is continuing to review data from the CIRRUS-1 study


    It is estimated that approximately 3.


    CFZ533 (iscalimab) is a new, fully human monoclonal antibody that targets CD40 (cluster of differentiation antigen 40)


    In June 2019, Novartis announced the early histological data of CFZ533 in kidney transplantation, indicating that CFZ533 may be more effective than tacrolimus, may extend the durability of the transplanted kidney, and may improve the long-term prognosis of kidney transplant patients


    The analysis showed that 60% of kidney transplant patients treated with CFZ533 had normal kidney histology at least 1 year after transplantation, while the proportion of patients treated with tacrolimus was 0




    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.